IL116084A - Freeze dried dosage forms containing ondansetron - Google Patents

Freeze dried dosage forms containing ondansetron

Info

Publication number
IL116084A
IL116084A IL11608495A IL11608495A IL116084A IL 116084 A IL116084 A IL 116084A IL 11608495 A IL11608495 A IL 11608495A IL 11608495 A IL11608495 A IL 11608495A IL 116084 A IL116084 A IL 116084A
Authority
IL
Israel
Prior art keywords
dosage forms
freeze dried
forms containing
dried dosage
ondansetron
Prior art date
Application number
IL11608495A
Other languages
English (en)
Other versions
IL116084A0 (en
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10764757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL116084(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Publication of IL116084A0 publication Critical patent/IL116084A0/xx
Publication of IL116084A publication Critical patent/IL116084A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Detergent Compositions (AREA)
  • Fertilizers (AREA)
IL11608495A 1994-11-22 1995-11-21 Freeze dried dosage forms containing ondansetron IL116084A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9423511A GB9423511D0 (en) 1994-11-22 1994-11-22 Compositions

Publications (2)

Publication Number Publication Date
IL116084A0 IL116084A0 (en) 1996-01-31
IL116084A true IL116084A (en) 2000-01-31

Family

ID=10764757

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11608495A IL116084A (en) 1994-11-22 1995-11-21 Freeze dried dosage forms containing ondansetron

Country Status (31)

Country Link
US (2) US5955488A (da)
EP (1) EP0793495B1 (da)
JP (1) JP3001264B2 (da)
KR (1) KR970706814A (da)
CN (1) CN1080118C (da)
AT (1) ATE193444T1 (da)
AU (1) AU704160B2 (da)
BE (1) BE1010250A3 (da)
BR (1) BR9509808A (da)
CY (1) CY2166B1 (da)
CZ (1) CZ285250B6 (da)
DE (1) DE69517332T2 (da)
DK (1) DK0793495T3 (da)
ES (1) ES2147309T3 (da)
FI (1) FI119355B (da)
FR (1) FR2727016B1 (da)
GB (2) GB9423511D0 (da)
GR (1) GR3033937T3 (da)
HK (1) HK1009591A1 (da)
HU (1) HU226891B1 (da)
IL (1) IL116084A (da)
IT (1) IT1282352B1 (da)
MX (1) MX9703735A (da)
NO (1) NO306893B1 (da)
NZ (1) NZ296982A (da)
PL (1) PL181179B1 (da)
PT (1) PT793495E (da)
RU (1) RU2159614C2 (da)
TW (1) TW398976B (da)
WO (1) WO1996015785A1 (da)
ZA (1) ZA959821B (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976577A (en) * 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
DE69738333T2 (de) * 1997-10-01 2008-11-27 Novadel Pharma Inc. Nichtpolares Spray zur bukkalen Verabreichung
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
WO2001039836A1 (en) * 1999-12-01 2001-06-07 Natco Pharma Limited A rapid acting freeze dired oral pharmaceutical composition for treating migraine
DE01991193T1 (de) * 2000-10-30 2004-07-08 Teva Pharmaceutical Industries Ltd. Neue kristall- und solvatformen von ondansetronhydrochlorid und verfahren zu deren herstellung
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
PT1499623E (pt) * 2002-04-29 2007-08-10 Teva Gyogyszergyar Zartkoeruee ''processo papa a preparação de 1, 2, 3, 9-tetra-hidro-9-metil-3- [(2-metil-1h-imidazol-1-il) metil] -4h-carbazol-4-ona''
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
CN1665803A (zh) * 2002-04-30 2005-09-07 特瓦药厂有限公司 新晶形的昂丹司琼及其制备方法、含有该新晶形的药物组合物以及用其治疗恶心的方法
CA2505990C (en) * 2002-11-15 2009-05-19 Helsinn Healthcare S.A. Palonosetron for the treatment of chemotherapy-induced emesis
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US7553853B2 (en) 2003-10-10 2009-06-30 Synthon Bv Solid-state montelukast
EP1709053B1 (en) * 2004-01-27 2011-04-06 Synthon B.V. Stable salts of olanzapine
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
US7829716B2 (en) * 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
ATE441669T1 (de) * 2004-05-24 2009-09-15 Genvault Corp Stabile lagerung von protein und stabile lagerung von nukleinsäure in wiedergewinnbarer form
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
WO2007020080A1 (en) * 2005-08-17 2007-02-22 Synthon B.V. A process for making olanzapine form i
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
AR057909A1 (es) * 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
EP1996552A1 (en) * 2006-03-17 2008-12-03 Synthon B.V. Montelukast amantadine salt
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
AR063043A1 (es) * 2006-09-29 2008-12-23 Synthon Bv Composicion farmaceutica de olanzapina
JP2010522135A (ja) 2006-10-09 2010-07-01 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
NZ576237A (en) * 2006-10-24 2011-12-22 Helsinn Healthcare Sa Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
WO2009130056A1 (en) * 2008-04-25 2009-10-29 Synthon B.V. Process for making montelukast intermediates
EP2253316B1 (en) * 2009-05-20 2013-08-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of an inner ear pathology with vestibular deficits
ES2664599T3 (es) * 2009-05-20 2018-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistas del receptor 5-HT3 de serotonina para uso en el tratamiento de trastornos vestibulares lesionales
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
NZ747201A (en) 2016-04-14 2023-02-24 Sensorion (+)-azasetron for use in the treatment of ear disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE24964T1 (de) * 1981-12-11 1987-01-15 Wyeth John & Brother Ltd Verfahren zur herstellung von festen formgegenstaenden.
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8917556D0 (en) * 1989-08-01 1989-09-13 Glaxo Group Ltd Medicaments
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
EP0450757A3 (en) * 1990-02-22 1993-09-15 Glaxo Group Limited Use of 5-hydroxytryptamine-antagonists in the treatment of mental disorders originating in childhood
US5046618A (en) * 1990-11-19 1991-09-10 R. P. Scherer Corporation Child-resistant blister pack

Also Published As

Publication number Publication date
TW398976B (en) 2000-07-21
WO1996015785A1 (en) 1996-05-30
JP3001264B2 (ja) 2000-01-24
GR3033937T3 (en) 2000-11-30
EP0793495A1 (en) 1997-09-10
IL116084A0 (en) 1996-01-31
FI119355B (fi) 2008-10-31
GB2295318A (en) 1996-05-29
NO306893B1 (no) 2000-01-10
ITRM950762A0 (da) 1995-11-20
HK1009591A1 (en) 1999-06-04
AU704160B2 (en) 1999-04-15
FR2727016A1 (fr) 1996-05-24
ZA959821B (en) 1996-07-31
CY2166B1 (en) 2002-08-23
DK0793495T3 (da) 2000-10-09
BE1010250A3 (fr) 1998-04-07
CZ285250B6 (cs) 1999-06-16
PT793495E (pt) 2000-10-31
IT1282352B1 (it) 1998-03-20
HUT77886A (hu) 1998-09-28
US5955488A (en) 1999-09-21
GB9423511D0 (en) 1995-01-11
GB9523667D0 (en) 1996-01-24
RU2159614C2 (ru) 2000-11-27
GB2295318B (en) 1998-10-28
FI972167A0 (fi) 1997-05-21
HU226891B1 (en) 2010-01-28
NO972325L (no) 1997-05-22
DE69517332D1 (de) 2000-07-06
FR2727016B1 (fr) 1998-04-03
FI972167A (fi) 1997-05-21
EP0793495B1 (en) 2000-05-31
PL320295A1 (en) 1997-09-15
AU4173996A (en) 1996-06-17
DE69517332T2 (de) 2000-11-30
NO972325D0 (no) 1997-05-21
CN1080118C (zh) 2002-03-06
ITRM950762A1 (it) 1997-05-20
US6063802A (en) 2000-05-16
NZ296982A (en) 1998-06-26
CN1171741A (zh) 1998-01-28
BR9509808A (pt) 1997-10-21
KR970706814A (ko) 1997-12-01
PL181179B1 (pl) 2001-06-29
ES2147309T3 (es) 2000-09-01
ATE193444T1 (de) 2000-06-15
JPH10508864A (ja) 1998-09-02
MX9703735A (es) 1998-07-31
CZ154997A3 (en) 1997-10-15

Similar Documents

Publication Publication Date Title
IL116084A (en) Freeze dried dosage forms containing ondansetron
WO1996015786A3 (en) Oral compositions containing ondansetron
AP1637A (en) Celecoxib compositions.
MY138227A (en) Valdecoxib compositions
MY133423A (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders
CA2205600A1 (en) Freeze-dried ondansetron compositions

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired